ArticleMetabolic brain disease2025
Eucommia ulmoides Oliver (Duzhong) extract ameliorates cerebral ischemic stroke in mice by remodeling intestinal microbiota and metabolites.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lysophosphatidylethanolamine (LysoPE) in health and disease: a narrative review of its pathophysiological mechanisms and translational potential as a biomarker.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cerebral stroke is characterized by high rate of disability and mortality. Emerging evidence indicates a relationship between acute ischemic stroke and alterations in the intestinal microbiota. Herein, the mechanism of Eucommia ulmoides extract (EUE) within ischemic stroke will be investigated from the perspective of intestinal microflora. In the study, EUE significantly reduced the area of cerebral infarction, ameliorated neurological deficits, and reduced neuronal death in mice. EUE reversed intestinal microbiota deregulation by regulating bacterial abundance, including up-regulating the abundance of the beneficial bacteria Dubosiella, Lachnospiraceae_NK4A136_group, and down-regulating the abundance of the deleterious bacteria Helicobacter, Bifidobacterium, Allobaculum, and Ileibacterium abundance. In addition, EUE also upregulated metabolites associated with inflammation and neuroprotection, including LysoPE, octadecyl fumarate, and adrenic acid. In in vitro experiments, the combination of EUE and LysoPE (0:0/20:4) significantly inhibited apoptosis, inflammatory responses, and oxidative stress levels in OGD cells compared to use alone. In conclusion, EUE significantly alleviated symptoms and neurological deficits in MCAO mice, and its mechanism is related to its involvement in remodeling intestinal microbiota and metabolism. EUE and LysoPE (0:0/20:4) are expected to be a potential novel regimen for the clinical treatment of cerebral ischemic stroke.
Indexed as
Identifiers
41288788What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.